Dr Israel Liberzon – Unravelling the Neural Networks Underpinning Posttraumatic Stress Disorder
Posttraumatic stress disorder (PTSD) is a prevalent psychiatric condition, significantly impacting the lives of millions of people globally. Sadly, symptoms often persist despite treatment. A better understanding of the brain abnormalities involved in PTSD is crucial to improving therapy development. Dr Israel Liberzon and his colleagues at the Texas A&M Health Sciences Centre have been working to uncover the dysfunctional neural networks that contribute to PTSD symptoms to inform the development of more effective interventions.
The Impact of Trauma
Being involved in or witness to a traumatic event at some stage in our lives is more than likely. Traumatic experiences – from military combat to road traffic accidents to violent assaults to natural disasters – are commonplace across the world and often result in debilitating consequences. One such consequence for individuals can be the development of posttraumatic stress disorder (PTSD).
Although clinical diagnostic criteria have changed over the decades (and will no doubt continue to evolve), PTSD is diagnosed according to core clusters of symptoms: intrusive and avoidant symptoms, negative cognitions, and hyperarousal. Despite the intensive research into PTSD to date, an understanding of the fundamental neurobiological abnormalities that are associated with PTSD and its symptoms has remained elusive. Without this understanding, current clinical treatments and interventions are often untimely and lacking in specificity. Improved knowledge of the underlying mechanisms of PTSD, however, would allow a move towards personalised treatment plans and even the prevention of PTSD.
Researching Posttraumatic Stress Disorder
Until recently, the understanding of the underlying mechanisms in PTSD was limited to the effects of the condition on physiological markers that could be readily measured, such as heart rate changes and the concentrations of stress hormones in blood and saliva. Genetic studies have identified genes that appear to be linked to PTSD, but these observations require confirmation as so far, they appear to be more preliminary and non-specific. Improvements in neuroimaging methods have enabled recent research efforts to focus on the effects of PTSD within specific neural circuits, which are the electro-chemical communication networks within the brain. Furthermore, how abnormalities in these circuits can influence the presentation of symptoms can be studied.
Powerful PTSD models have been developed from such research, including the abnormal fear learning model, exaggerated threat detection model and the diminished emotional regulation/executive function model, which are each linked to specific neural circuits and correspond to underlying molecular and cellular mechanisms. However, these experimental models leave several aspects of PTSD unexplained, including complex symptoms and substantiated neurobiological findings.

The Altered Contextualisation Hypothesis
Dr Israel Liberzon and his colleagues have identified the need for a PTSD model that would encompass and explain multiple aspects and presentations of the disorder. ‘Ultimate cure or recovery is possible only if the underlying mechanism of the disease is fully uncovered,’ notes Dr Liberzon. The team proposed a new altered contextual processing (CP) model, focussing on the deficits in the neural circuits that are responsible for processing contextual information and regulating emotional responses. This comprehensive CP model will provide a more precise neurobiological understanding, ultimately contributing to improved success in translating research into clinical interventions.
Contextual processing involves perception and cognitive interpretation of general, emotional and other signals in a situation, to determine its overall meaning, for example ‘safe’ or ‘dangerous’ environment. Various signals from a given situation or environment are assembled and stored as contextual representations, which can be later utilised to produce an appropriate response according to the needs of a future situation. A lack of precision and flexibility in these representations, necessary for correctly inferred circumstances and appropriate behavioural responses, is likely responsible for a broad range of symptoms in PTSD.

Investigating the Neural Networks Involved
There is much research to suggest that dysfunction in the context processing circuitry plays a central role in the mechanisms underlying PTSD, and several specific brain regions have been identified as potential contributors.
The hippocampus, responsible for establishing new memories, appears to contribute to increased vigilance and arousal in PTSD sufferers by excessively recalling traumatic experiences even in incorrect contexts. The prefrontal cortex, interconnected with the hippocampus, seems to accumulate the features of similar contexts to connect different experiences over time. Dysfunction in this hippocampal-pre-frontal-thalamic network could induce misinterpretation and fear learning of innocuous cues as traumatic signals, causing disproportionate fear behaviours and emotional overreaction in PTSD. Dr Liberzon and his colleagues investigated the possible role of this hippocampal-pre-frontal-thalamic network in relation to their CP model; they found a diminished ability to learn appropriate fear/safety behaviours and reactions, alongside reduced activity in these brain regions of individuals with PTSD. The team proposed that such a dysfunctional network could lead to the inappropriate linking of erroneous emotions to different contexts.
In his published work, Dr Liberzon speculates ‘if a context is identified as “unsafe,” attention is focussed on potential threat cues, leading to hypervigilance; but if contextual information that should alert one to danger is missed, this might lead to recklessness and re-traumatisation,’ linking the neurobiological abnormalities to previously unexplained aspects of PTSD. In this way, the CP model provides a robust framework for integrating underlying mechanisms with multitude of clinical presentations in PTSD. Genetic and animal model studies have corroborated Dr Liberzon’s findings and hypotheses, with new research consistently implicating the hippocampal-pre-frontal-thalamic circuitry in the genetic and developmental defects linked to PTSD.
Results emerging from electrophysiological studies, where the electrical inputs and signals between cells and anatomical structures are measured, have indicated that disrupted hippocampal-pre-frontal-thalamic network communication contributes to abnormalities in the stress hormone systems through sleep disturbance, leading to interrupted memory formation and consolidation in PTSD. Dr Liberzon’s CP model of PTSD is therefore proving to be a general, parsimoneous explanation for the genetic, hormonal, and psychophysiological mechanisms of the disorder.
‘We cannot wait for the ultimate solution, and best available care must be developed and administered.’

Tackling the Spectrum of Symptoms in Treatment
Using the concept of intermediate phenotypes (IPs) – clinical presentations that are linked to an underlying dysfunctional neurological mechanism – Dr Liberzon suggests that disorders like PTSD should be considered more like syndromes, that combine specific neurobiological IPs that produce a unique version of the condition in affected individuals. He states that ‘identifying distinct IPs will facilitate the development of more valid animal models needed to further dissect the mechanistic neurobiology of all “types” of PTSD,’ while emphasising that ‘further elucidation of the cellular and/or molecular mechanisms is critical.’
Working on the basis of previous research, Dr Liberzon and his colleagues have most recently conducted a study assessing volume abnormalities in different brain regions implicated in PTSD. Coming together with scientists and clinicians across the globe, Dr Liberzon and the team have been able to perform one of the most comprehensive analyses to date, assessing the effects of PTSD in the brain regions of nearly 1400 affected individuals. They found PTSD to be associated with smaller volumes in brain regions involved in emotion, sensory information and memory processing, with greater volume reduction in these areas corresponding to increasing severity of the PTSD symptoms.
‘Our findings support current thinking on deficits in emotion neuro-circuits in PTSD and shed new light on the involvement of sensory brain circuits’ notes Dr Liberzon. Such findings will be crucial in identifying individualised presentations of the disorder, or dominant symptoms and dysfunctional mechanisms in a given patient, leading towards the potential for a more specifically targeted treatment and a more personalised medicine approach.
As both a physician and a scientist, Dr Liberzon is dedicated to easing the suffering of individuals with mental health difficulties, particularly those with PTSD. ‘We cannot wait for the ultimate solution, and best available care must be developed and administered,’ he explains.

Future Paths for Research
Now a Professor and Department Head of Psychiatry at the Texas A & M Health Sciences Centre in the USA, Dr Liberzon plans to continue his research with ‘rigour and intensity’, having identified the hippocampal-pre-frontal-thalamic circuitry as a key neural circuit affected in PTSD patients.
Dr Liberzon already has substantial backing to explore this promising avenue of research, and intends to continue working towards better treatment strategies and intervention approaches in PTSD, in combination with personalised medicine approaches. ‘This was a challenging but immensely gratifying path,’ notes Dr Liberzon. He indicates that future research will also investigate links with PTSD to other diseases, such as heart disease and the involvement of inflammation, to improve the understanding of the impact of co-existing diseases on the severity and presentation of PTSD, since the effects of these disorders add further to the detriment of the overall health of an individual.
Dr Liberzon hopes that continuing a career in translational science, engaging in research and clinical practice simultaneously, will prove effective in easing the suffering associated with PTSD more efficiently.
Reference
https://doi.org/10.33548/SCIENTIA665
Meet the researcher

Dr Israel Liberzon
Department of Psychiatry
Texas A&M Health Sciences Center
Bryan, TX
USA
Dr Israel Liberzon received his MD in Israel at Tel Aviv University after studying Biology. His postdoctoral training began in Israel, before moving to the University of Michigan in the USA, where he was appointed Professor of Psychiatry and Psychology. Dr Liberzon’s defining interests stem from his career as a physician-scientist, devoting his work to easing the suffering of individuals with PTSD by researching the risk and resilience factors important in the disorder. Having developed the most widely used animal model of PTSD, he continues to develop new hypotheses on the underlying dysfunctional mechanisms to improve treatment strategies. As an expert in his field and co-leader of the development of an international PTSD group, Dr Liberzon has been invited to lecture around the world, training the next generation of successful researchers. Now, as Professor of Psychiatry at the Texas A&M Health Sciences Center, Dr Liberzon intends to continue studying the neurobiology of individual presentations of PTSD taking into account the impact of other health conditions on the severity of the disorder.
CONTACT
W: https://health.tamu.edu/experts/israel-liberzon.html
FUNDING
Department of Defense
National Institute of Mental Health
National Center for Complementary and Integrative Health
FURTHER READING
S A Perrine, I Liberzon, Editorial: Pre-clinical Models of PTSD, Frontiers in Behavioural Neuroscience, 2019, 13, 237.
I Liberzon, Searching for Intermediate Phenotypes in Posttraumatic Stress Disorder, Biological Psychiatry, 2018, 83, 10, 797–799.
I Liberzon, J L Abelson, Context Processing and the Neurobiology of Post-Traumatic Stress Disorder, Neuron, 2016, 92. 14–30.

Want to republish our articles?
We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more
Creative Commons Licence
(CC BY 4.0)
This work is licensed under a Creative Commons Attribution 4.0 International License. 
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
More articles you may like
Assoc Prof. Nicholas Brown | Rethinking Prostate Care: A New Frontier in Treating Benign Prostatic Hyperplasia
For millions of men, ageing brings with it a set of frustrating and often disruptive urinary symptoms. These symptoms, caused by benign prostatic hyperplasia, or BPH, can affect sleep, confidence, and overall quality of life. Traditionally, treatment follows a familiar path. Patients begin with medications, often for years, and may eventually progress to surgery if symptoms worsen. Yet this pathway is not without its drawbacks. Medications can cause side effects, while surgery carries risks and recovery time. In recent years, a minimally invasive interventional radiology procedure called prostate artery embolisation, or PAE, has begun to challenge this traditional model. At the forefront of this shift is a collaborative research group, led by Dr. Nicholas Brown of the University of Queensland, whose series of P-EASY studies has explored whether PAE could transform how BPH is treated, particularly at earlier stages.
Jean Lycke | Addressing Unmet Medical Needs in Mucosal Disease: A Close-to-Market Innovation Approach
Recurrent Aphthous Stomatitis (RAS) is an oral condition characterized by one or several painful mucosal ulcers. RAS affects a large proportion of the population and has a point prevalence of approximately 2–3%, daily. The etiology remains unknown, and there is currently no curative treatment. Most patients experience recurring episodes over time, with each episode typically lasting up to a week. Here, we describe the development of a mucoadhesive patch which, when applied over a RAS ulcer, provides rapid pain relief. The patch is easy for patients to apply when symptoms begin and has the potential to be used as an over-the-counter product. The development of the Mucocort mucoadhesive patch is an example of a Close-to-Market innovation strategy that embraces simplicity within a complex healthcare system. By simplifying the product concept, the team has reduced the number of regulatory steps required before market approval. This MedTech/Pharma innovation model, known as the “4R” framework – Re-purposing, Re-formulation, Re-positioning, and Re-patenting – has guided the program from concept to commercialization. In addition to the biodegradable mucoadhesive patch developed for RAS ulcers, the team is extending the innovation concept to a mucoadhesive gel formulation for the prevention and treatment of chemotherapy-induced mucositis. This gel-based program is being commercialized separately through MucoShield.
The Translational Asian Agerelated Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care
Age-related macular degeneration, often abbreviated as AMD, is one of the leading causes of vision loss among older adults worldwide. In Asia, where populations are ageing rapidly, its impact is particularly profound. For many, the disease quietly erodes central vision, making everyday activities such as reading, driving, and recognising faces increasingly difficult. Against this backdrop, the Translational Asian Age-related Macular Degeneration Programme, or TAAP for short, has emerged as a bold and ambitious effort to confront the disease headon. Now in its second phase, TAAP-2 represents a significant evolution in both scientific scope and clinical ambition.
Ms. Aikaterini Dritsoula | Looking Beyond Snoring: How Hidden Airway Problems Shape Children’s Sleep
For many parents, a child’s snoring may seem harmless, even endearing. Yet in some cases, it signals something more serious. Obstructive sleep apnoea is a condition in which a child’s breathing is repeatedly disrupted during sleep. These interruptions can affect growth, behaviour, and learning. Children with this condition may toss and turn at night, struggle to concentrate during the day, or show signs of hyperactivity and fatigue. Traditionally, enlarged tonsils and adenoids have been seen as the main culprits. Surgery to remove them has long been considered the standard treatment. However, research led by Consultant ENT Surgeon Ms. Aikaterini Dritsoula of The Leeds Teaching Hospitals NHS Trust invites us to look deeper. Her work suggests that the story is often more complex, especially in very young children.



